<DOC>
	<DOCNO>NCT02423603</DOCNO>
	<brief_summary>Normally , cell human body divide orderly way . However cancer cell , important protein , help control cell growth , start behave abnormally result faster growth multiplication . In study , look protein call AKT help cancer cell develop . Blocking action AKT drug like AZD5363 may slow stop cancer grow . The development AZD5363 intend provide new treatment option patient cancer . The standard chemotherapy agent , Paclitaxel , give destroy cancer cell . AZD5363 may also make cancer sensitive Paclitaxel make agent effective . A gene call PIK3CA important relationship AKT . In tumours gene alter , say 'mutated ' , response AZD5363 may better . PIK3CA mutation find commonly breast cancer , test presence mutation blood tumour tissue sample ask provide . This study also look relationship tumour PIK3CA mutation effect treatment .</brief_summary>
	<brief_title>PAKT : AZD5363 Combination With Paclitaxel Triple-Negative Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>The term triple-negative breast cancer ( TNBC ) generally use define tumour express oestrogen receptor ( ER ) , progesterone receptor ( PR ) HER2 receptor . This subtype comprise 10-15 % breast cancer . TNBC aggressive clinical course , share feature basal-like tumour , poor outcome compare subtypes . Clinically , TNBC 's challenge treat role endocrine HER2-directed therapy . Chemotherapy effective , neo-adjuvant study show despite initial chemo-sensitivity , TNBC 's still worse outcome , particularly woman pathologically confirm complete response achieve . Consequently , clear need develop specific treatment strategy subgroup TNBC 's early advanced disease set . AZD5363 potent , selective inhibitor kinase activity serine/threonine AKT/PKB ( protein kinase B ) develop potential treatment solid haematological malignancy . AKT part AGC family kinase . Mammalian cell express three closely related AKT isoforms : AKT1 ( PKBa ) , AKT2 ( PKBß ) AKT3 ( PKBgamma ) , encode different gene . This placebo-controlled , multi-centre , 2-arm randomise phase II trial Paclitaxel + AZD5363 versus Paclitaxel + placebo patient triple-negative ( ER-negative , PR-negative/unknown , HER2-negative ) advance metastatic breast cancer . Patients randomise either Arms Paclitaxel + Placebo OR Paclitaxel + AZD5363 . Randomisation stratify follow criterion : - Number metastatic site ( &lt; 3 , =3 ) - ( Neo ) Adjuvant chemotherapy ( end ( neo ) adjuvant chemotherapy =12 month ago , end ( neo ) adjuvant chemotherapy &gt; 12 month prior ( neo ) adjuvant chemotherapy ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Written inform consent prior admission study 2 . Women , age &gt; 18 year 3 . Histologically confirm breast cancer 4 . Metastatic locally recurrent disease ; locally recurrent disease must amenable resection curative intent ( patient consider suitable surgical ablative technique follow potential downstaging study treatment eligible ) 5 . Patient must At least one lesion , previously irradiate , measure accurately baseline ≥ 10mm long diameter ( except lymph node must short axis ≥15mm ) CT , magnetic resonance imaging ( MRI ) suitable accurate repeat measurement , OR lytic mixed bone lesion absence measurable disease define ; patient sclerotic/osteoblastic bone lesion absence measurable disease eligible . 6 . Radiological clinical evidence recurrence progression 7 . Triplenegative disease , define tumour cell Negative ER &lt; 1 % tumour cell positive ER IHC IHC score ≥2 Negative PR &lt; 1 % tumour cell positive PR IHC IHC score ≥2 PR unknown Negative HER2 0 , 1+ 2+ intensity IHC evidence amplification ISH 8 . Formalin fix paraffin embed tumour sample primary recurrent cancer must available central test 9 . Patients must able swallow retain oral medication 10 . Haematologic biochemical index within protocol specify range 11 . ECOG performance status 02 12 . Nonchildbearing potential . If patient childbearing potential , must negative serum pregnancy test agree use adequate contraception 13 . Willing able provide write informed consent 1 . Patients confirm brain metastasis history primary central nervous system tumours signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastasis . 2 . Prior chemotherapy metastatic breast cancer 3 . Radiotherapy wide field radiation within 4 week first dose study medication 4 . Prior treatment PI3K inhibitor , AKT inhibitor mTOR inhibitor 5 . Prior treatment paclitaxel docetaxel ( neo ) adjuvant set within 12 month inclusion study 6 . Preexisting sensory motor polyneuropathy ≥ Grade 2 accord CTCAE 7 . Malabsorption syndrome condition would interfere enteral absorption 8 . Clinically significant pulmonary dysfunction 9 . Prolongation define QTc interval &gt; 470msecs significant abnormality rhythm , conduction morphology rest ECG include 2nd degree ( Type II ) 3rd degree AV block bradycardia ( ventricular rate &lt; 50 beats/min ) 10 . Any factor increase risk QTc prolongation risk arrythmic event 11 . Experience follow procedure condition precede 6 month : coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , angina pectoris , congestive heart failure NYHA Grade ≥2 , cardiac ejection fraction outside institutional range normal &lt; 50 % 12 . Clinically significant abnormality glucose metabolism 13 . Patients proteinuria creatine &gt; 1.5xULN concurrent creatinine clearance &lt; 50mL/min 14 . Exposure potent inhibitor inducer substrate CYP3A4 substrates CYP2D6 within 2 week first dose study treatment 15 . Concurrent treatment experimental drug participation another clinical trial investigational drug within 30 day prior study entry 16 . Psychological , familial , sociological geographical condition permit compliance study protocol . 17 . Detained person prisoner 18 . Pregnant nursing woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>AKT Inhibitor</keyword>
	<keyword>Advanced</keyword>
	<keyword>AZD5363</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>PAKT</keyword>
</DOC>